MedTrace Logo

Evaluation of the Potential Impact of an Artificial Intelligence Solution in Second Reading of Organized Screening.

NCT06479772 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55589

Last updated 2024-06-28

No results posted yet for this study

Summary

Based on data from a series of patients who underwent screening mammography with a "normal" or "benign" first-reading result. The main objective of the study is to evaluate the possibilities of subtracting from the second reading of breast cancer screening a population of examinations for which the risk of discovering cancer is close to zero, using an AI system (here the MammoScreen™ system).

Conditions

  • Breast Cancer Female

Sponsors & Collaborators

  • Vivactis M2Research

    collaborator INDUSTRY

  • GCS Ramsay Santé pour l'Enseignement et la Recherche

    lead OTHER

Principal Investigators

  • Christophe TOURASSE, MD · Hôpital Privé Jean Mermoz

Eligibility

Min Age
50 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-10
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06479772 on ClinicalTrials.gov